Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 4/20 | 0.50 |
| ▸ | LCK | P06239 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | JAK3 | P52333 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 12/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
| ▸ | NRP1 | O14786 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564842 | 0.90 | AURKA (0.48) | TNK2LCKKDRJAK3AURKA | |
| SCHEMBL3562107 | 0.84 | AURKA (0.62) | TNK2LCKKDRJAK3AURKA | |
| SCHEMBL3563328 | 0.81 | AURKA (0.51) | TNK2AURKACHEK1MAP2K1MEN1 | |
| SCHEMBL13399906 | 0.81 | AURKA (0.66) | AURKA | |
| SCHEMBL3566434 | 0.79 | ALDH1A1 (0.58) | TNK2LCKKDRJAK3AURKA | |
| SCHEMBL3579856 | 0.78 | CHEK1 (0.47) | TNK2AURKACHEK1MAP2K1MEN1 | |
| SCHEMBL3576476 | 0.78 | KMT2A (0.58) | TNK2LCKAURKACHEK1MAP2K1 | |
| SCHEMBL3566479 | 0.78 | KDM4E (0.53) | TNK2LCKKDRJAK3AURKA | |
| SCHEMBL3572103 | 0.77 | KDM4E (0.52) | TNK2LCKKDRJAK3AURKA | |
| SCHEMBL3568701 | 0.77 | CYP1A2 (0.42) | TNK2KDRJAK3AURKACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674907-B2 | Furanopyridine derivatives and methods of use | AMGEN INC. (US) | 2010-03-09 | — | — | US | claimed |
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | AMGEN INC. | 2006-03-02 | — | — | US | claimed |
| US-7674907-B2 | Furanopyridine derivatives and methods of use | AMGEN INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | AMGEN INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | LCK, NFATC1, MINK1 | TNK2 22/4885LCK 1/4885KDR 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.